Phuturdex › Diseases › Neurodegenerative Diseases
Drugs in development · updated 30 October 2026
Neurodegenerative Diseases: drugs in development
As of 30 October 2026 there are 29 active clinical trials (recruiting or ongoing, phases I–III) on 25 drugs for neurodegenerative Diseases. 21 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AmlenetugLu AF82422 | III | 2 | NCT06706622 |
| Ambroxol Hydrochloride | III | 1 | NCT05778617 |
| Ecopipam | III | 1 | NCT06021522 |
| ML-007C-MA | II | 2 | NCT06887192 |
| VX-670 | I–II | 2 | NCT06185764 |
| Allopregnanolone | II | 1 | NCT04838301 |
| ALN-6457 | I–II | 1 | NCT07832370 |
| BIA 28-6156 | II | 1 | NCT05819359 |
| BMS-986446 | II | 1 | NCT06268886 |
| FosigotifatorABBV-CLS-7262 | I–II | 1 | NCT05757141 |
| GS010 | II | 1 | NCT07303296 |
| NBI-1117567 | II | 1 | NCT07832383 |
| Neflamapimod | II | 1 | NCT07033481 |
| VIM0423 | II | 1 | NCT07804615 |
| Votoplam | II | 1 | NCT06254482 |
| ALN-HTT02 | I | 1 | NCT06585449 |
| LY3439539 | I | 1 | NCT07598370 |
| LY3954068 | I | 1 | NCT06297590 |
| NIO752 | I | 1 | NCT05469360 |
| ZR001 | I | 1 | NCT07718659 |
| 18F-FCOB04 | Early I | 1 | NCT07470710 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DonanemabKisunla® | III | 3 | NCT05508789 |
| 18F-AV-1451[18F] Flortaucipir, Flortaucipir F18 | II–III | 2 | NCT03143374 |
| DexamethasoneDexametasone, Dextenza | III | 1 | NCT05738486 |
| RiluzoleExservan®, Tiglutik Kit® | I | 1 | NCT07093268 |
Sorted by most advanced phase and number of active trials.
All 25 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Alzheimer's disease 157 drugs
- Parkinson's disease 104 drugs
- Amyotrophic lateral sclerosis 79 drugs
- Myasthenia gravis 49 drugs
- Cognitive dysfunction 94 drugs
- Neurofibromatosis 1 28 drugs
- Dementia 54 drugs
- Multiple system atrophy 19 drugs
- Spinal muscular atrophies 12 drugs
- Friedreich ataxia 9 drugs
- Plexiform neurofibroma 12 drugs
- Huntington's disease 14 drugs
Broader categories
- Nervous System Diseases 39 drugs
- Brain Diseases 23 drugs
- Central nervous system disease 38 drugs
- Mental disorder 24 drugs
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Neurologic Manifestations 15 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D019636 “Neurodegenerative Diseases”.